Expression of Proteasome Activator REGγ in Human Laryngeal Carcinoma and Associations with Tumor Suppressor Proteins |
Li, Li-Ping
(Department of Otorhinolaryngology and Translational Neuroscience Center, West China Hospital of Sichuan University)
Cheng, Wei-Bo (Department of Pathology, West China School of Public Health, Sichuan University) Li, Hong (The Joint Research Center, West China Second University Hospital and University of Hong Kong) Li, Wen (Department of Otorhinolaryngology and Translational Neuroscience Center, West China Hospital of Sichuan University) Yang, Hui (Department of Otorhinolaryngology and Translational Neuroscience Center, West China Hospital of Sichuan University) Wen, Ding-Hou (Department of Otorhinolaryngology and Translational Neuroscience Center, West China Hospital of Sichuan University) Tang, Yue-Di (Department of Otorhinolaryngology and Translational Neuroscience Center, West China Hospital of Sichuan University) |
1 | Ciechanover A (1998). The ubiquitin-proteasome pathway: on protein death and cell life. EMBOJ, 17, 7151-60. DOI ScienceOn |
2 | Ciechanover A, Orian A, Schwartz AL (2000). Ubiquitinmediated proteolysis: biological regulation via destruction. Bioessays, 22, 442-51. DOI |
3 | El-Deiry WS, Harper JW, O'Connor PM, et al (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res, 54, 1169-74. |
4 | Finlay CA, Hinds PW, Tan TH, et al (1988). Activating mutations for transformation by p53 produce a gene product that forms an HSC 70-p53 complex with an altered half-life. Mol Cell Biol, 8, 531-9. |
5 | Harper JW, Adami GR, Wei N, et al (1993). The p21 cdkinteracting protein Cip1 is a potent inhibitor of G1cyclindependent kinases. Cell, 75, 805-16. DOI ScienceOn |
6 | Hochstrasser M (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol, 7, 215-23. DOI |
7 | Roessler M, Rollinger W, Mantovani-Endl L, et al (2006). Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics, 5, 2092-101. DOI |
8 | Jin YT, Kayser S, Kemp BL, et al (1998). The Prognostic Significance of the Biomarkers p21WAF1/CIP1, p53, and bcl-2 in Laryngeal Squamous Cell Carcinoma. Cancer, 82, 2159-65. DOI |
9 | Lane DP (1992). Cancer: p53, guardian of the genome. Nature, 358, 15-6. DOI ScienceOn |
10 | Reich NC, Oven M, Levine AJ (1983). Two distinct mechanisms regulate the levels of cellular tumor antigen p53. Mol Cell Biol, 3, 2143-50. |
11 | Sharpless NE and DePinho RA (2002). p53: good cop/bad cop. Cell, 110, 9-12. DOI ScienceOn |
12 | Li X, Amazit L, Long W, et al (2007). Ubiquitin- and ATPindependent proteolytic turnover of p21 by the REGgammaproteasome pathway. Mol Cell, 26, 831-42. DOI |
13 | Li X, Lonard DM, Jung SY, et al (2006). The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell, 124, 381-92. DOI |
14 | Luo H, Wong J, Wong B (2010). Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy. Cardiovasc Res, 85, 347-56. DOI |
15 | Roninson IB (2002). Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett, 179, 1-14. DOI |
16 | Sarafoleanu D, Postelnicu V, Iosif C, et al (2009). The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. J Med Life, 2, 219-26. |
17 | Shunqian J, Qimin Z (2002). Oncomolecularbiology is the forefront of basic medical research. World Chin J Dig, 10, 678-80. |
18 | Mao I, Liu J, Li X, et al (2008). REGgamma, a proteasome activator and beyond? Cell Mol Life Sci, 65, 3971-80. DOI |
19 | Murata S, Kawahara H, Tohma S, et al (1999). Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem, 274, 38211-5. DOI |
20 | Okamura T, Taniguchi S, Ohkura T, et al (2003). Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J Clin Endocrinol. Metab, 88, 1374-83. DOI |
21 | Soza A, Knuehl C, Groettrup M, et al (1997). Expression and subcellular localization of mouse 20S proteasome activator complex PA28. FEBS Lett, 413, 27-34. DOI |
22 | Tomohisa O, Shin-Ichi T, Tsuyoshi O, et al (2003). Abnormally high expression of proteasome activator-cin Thyroid neoplasm. J Clin Endocrinol Metab, 88, 1374-83. DOI |
23 | Wang XY, Tu SF, Tan JX, et al (2009). REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med Oncol, 28, 31-41. |
24 | Weinberg WC, Denning MF (2002). P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med, 13, 453-64. DOI |
25 | Zhang Z, Zhang R (2008). Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J, 27, 852-64. DOI |
26 | Powell J, Robin PE (1983). Cancer of the head and neck: the present state. In: Head and Neck Cancer. Rhys Evans P, Robin PE & Fielding JWL (eds). Castle House: Tunbridge Wells. |
27 |
Wojcik C, Tanaka K, Paweletz N, et al (1998). Proteasome activator (PA28) subunits, |
28 | Ying H, Furuya F, Zhao L, et al (2006). Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest, 116, 2972-84. DOI |
29 | Realini C, Jensen CC, Zhang Z, et al (1997). Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J Biol Chem, 272, 25483-92. DOI |
30 |
Zhang M, Gan L, Ren GS (2012). REG |
31 | Ciechanover A (1994). The ubiquitin-proteasome proteolytic pathway. Cell, 79, 13-21. DOI ScienceOn |
32 | Ahn K, Erlander M, Leturcq D, et al (1996). In vivo characterization of the proteasome regulator PA28. J Biol Chem, 271, 18237-42. DOI |
33 | Barton LF, Runnels HA, Schell TD, et al (2004). Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol, 172, 3948-54. DOI |
34 | Bianchi S, Paglierani M, Zampi G, et al (1993). Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer, 72, 120-5. DOI |
35 | Bosari S, Viale G, Roncalli M, et al (1995). p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol, 147, 790-8. |
36 | Chen X, Barton LF, Chi Y, et al (2007). Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell, 26, 843-52. DOI |
![]() |